Tozorakimab Reduces COPD Exacerbations in Phase 3 MIRANDA Trial

Summary: A new medicine called tozorakimab is showing great promise for people with chronic obstructive pulmonary disease (COPD). In a large study called MIRANDA, this treatment helped lower the number of severe breathing attacks in patients. It works by blocking a specific protein in the body, called IL-33, that causes swelling and mucus buildup in the lungs. The medicine worked well for both former and current smokers, no matter how severe their lung damage was. This could be a game-changer for helping COPD patients breathe easier and live more comfortably.

Source: rssapp-empr-com URL: empr.com/news/tozorakimab-reduces-copd-exacerbations-in-phase-3-miranda-trial/ (opens in new tab)